Eteplirsen

依特立生

Report date: 2026/03/10 20:00:16
NMEFirst In Class

Base Information

Drug NameEteplirsen
Drug Alias NameeteplirsenumVyondys 51Exondys 51AVI-4658
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionDystrophin pre-mRNA inhibitorsDystroglycan stimulants
TargetsDystrophin pre-mRNADystroglycan
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsMuscular Dystrophy, Duchenne
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/09/19
Country/TerritoryCzechiaBelgiumUnited States +[27
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSarepta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSarepta Therapeutics Inc
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeM09AX06